A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease

Journal of Gastroenterology

Volumn 43, Issue 6, 2008, Pages 448-456

  Hongo, Michio ^a   Kinoshita, Yoshikazu ^b   Haruma, Ken ^c  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

GERD; H2RA; NERD; Symptomatic resolution

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONEROSIVE REFLUX DISEASE; OPTIMAL DRUG DOSE; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STOMACH ACID; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

DOUBLE-BLIND METHOD; FAMOTIDINE; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED;

EID: 47349086137     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-008-2186-5     Document Type: Article

References (36)

1. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999;44Suppl 2:S1-S16.
2. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl 1993;199:18-21.
3. Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998;104:252-258.
4. Prasad M, Rentz AM, Revicki DA. The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life. Pharmacoeconomics 2003;21:769-790.
5. Wiklund I, Bardhan KD, Muller-Lissner S, Bigard MA, Bianchi Porro G, Ponce J, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. Ital J Gastroenterol Hepatol 1998;30:19-27.
6. Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003;18:767-776.
7. Shi G, Bruley des Varannes S, Scarpignato C, Rhun ML, Galmiche JP. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995;37:457-464.
8. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, et al. Endoscopic assessment of oesophagitis; clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-180.
9. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther 2003;17:537-545.
10. Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98(3 Suppl):S2-S7.
11. Miwa H, Minoo T, Hojo M, Yaginuma R, Nagahara A, Kawabe M, et al. Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases. Aliment Pharmacol Ther 2004;20Suppl 1:112-117.
12. Kinoshita Y, Kawanami C, Kishi K, Nakata H, Seino Y, Chiba T. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut 1997;41:452-458.
13. Hongo M. Reflux esophagitis and Helicobacter pylori: East and West. J Gastroenterol 2004;39:909-910.
14. Tahir H, Sumii K, Haruma K, Tari A, Uemura N, Shimizu H, et al. A statistical evaluation on the age and sex distribution of basal serum gastrin and gastric acid secretion in subjects with or without peptic ulcer disease. Hiroshima J Med Sci 1984;33:125-130.
15. Feldman M, Richardson CT, Lam SK, Samloff IM. Comparison of gastric acid secretion rates and serum pepsinogen I and II concentrations in occidental and oriental duodenal ulcer patients. Gastroenterology 1988;95:630-635.
16. Goldschmiedt M, Barnett CC, Schwarz BE, Karnes WE, Redfern JS, Feldman M. Effect of age on gastric acid secretion and serum gastrin concentrations in healthy men and women. Gastroenterology 1991;101:977-990.
17. Fujiwara Y, Higuchi K, Shiba M, Yamamori K, Watanabe Y, Sasaki E, et al. Differences in clinical characteristics between patients with endoscopy-negative reflux disease and erosive esophagitis in Japan. Am J Gastroenterol 2005;100:754-758.
18. Fujiwara Y, Higuchi K, Watanabe Y, Shiba M, Watanabe T, Tominaga K, et al. Prevalence of gastroesophageal reflux disease and gastroesophageal reflux disease symptoms in Japan. J Gastroenterol Hepatol 2005;20:26-29.
19. Mishima I, Adachi K, Arima N, Amano K, Takashima T, Moritani M, et al. Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese. Scand J Gastroenterol 2005;40:1005-1009.
20. Wada T, Sasaki M, Kataoka H, Tanida S, Itoh K, Ogasawara N, et al. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: Randomizedcontrolled study of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005;21:2-9.
21. Arnestad JS, Kleveland PM, Waldum HL. In single doses ranitidine effervescent is more effective than lansoprazole in decreasing gastric acidity. Aliment Pharmacol Ther 1997;11:355-358.
22. Hedenstrom H, Alm C, Kraft M, Grahnen A. Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers. Aliment Pharmacol Ther 1997;11:1137-1141.
23. Khoury RM, Katz PO, Castell DO. Post-prandial ranitidine is superior to post-prandial omeprazole in control of gastric acidity in healthy volunteers. Aliment Pharmacol Ther 1999;13:1211-1214.
24. Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol 2003;98(3 Suppl):S31-S39.
25. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005;2:CD003245.
26. Joh T, Miwa H, Higuchi K, Shimatani T, Manabe N, Adachi K, et al. Validity of endoscopic classification of nonerosive reflux disease. J Gastroenterol 2007;42:444-449.
27. Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, Ito M, et al. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: A multicenter study from Japan. Aliment Pharmacol Ther 2007;26:69-77.
28. Ebi O. Implementation of new Japanese GCP and the quality of clinical trials - from the standpoint of the pharmaceutical industry (in Japanese with English abstract). Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 1997;24:1883-1891.
29. Hoshihara Y. Endoscopic findings of GERD (in Japanese with English abstract). Nippon Rinsho (Jpn J Clin Med) 2004;62:1459-1464.
30. Nakamura T, Shirakawa K, Masuyama H, Sugaya H, Hiraishi H, Terano A. Minimal change oesophagitis: A disease with characteristic differences to erosive oesophagitis. Aliment Pharmacol Ther 2005;21:19-26.
31. Hongo M. Minimal changes in reflux esophagitis: Red ones and white ones. J Gastroenterol 2006;41:95-99.
32. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006;3:CD002095.
33. Richter JE, Kovacs TOG, Greski-Rose PA, Huang B, Fisher R. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 1999;13:795-804.
34. Wolfe MM, Sachs G. Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000;118(2 Suppl 1):S9-S31.
35. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 1983;24:270-276.
36. Cederberg C, Ekenved G, Lind T, Olbe L. Acid inhibitory characteristics of omeprazole in man. Scand J Gastroenterol 1985;20Suppl 108:105-112.